Demonstrated commercial success
Utilising the technology to minimise wound pain in humans.
Presently, there is no commercially available product for humans that can be sprayed onto wounds in emergency situations to promptly alleviate pain, minimise bleeding, provide antisepsis and create a protective barrier.
Solfen-Tech® is a patented, four-way combination technology platform for wound care and pain mitigation. The platform technology allows for multiple actives to be formulated together, held in solution, creating a stable viscous matrix, which enables spray and stay.
Market opportunity addresses a significant unmet need in wound care.
The Solfen-Tech® platform technology delivers to multiple, clear and distinct markets.
Target markets:
- Acute Wounds
- Burns
- Surgical and Traumatic Wounds: Lacerations, Skin Tears, Surgical Wounds, Post Procedure, Abrasions & Minor Cuts and Grazes
- Chronic Wounds
- Venous Leg Ulcers
- Pressure Ulcers
- Diabetic and other Ulcers
- End Use
- Hospital
- Speciality Clinics
- Home Health Care
- Other unique environments, including the Military
Current position
- Multi-Indication Pipeline
- Phase II trials are ongoing
- Low-cost Phase III studies
Addressable Global Wound Care Market is expected to grow at a CAGR of 4.12% over the forecast period to reach an estimated value of AUD 46.3 billion by 2030.1
Supported by trial data from the approved animal product (Tri-Solfen®), we have initiated the development and regulatory process, for Medi-Solfen®, for several indications in humans1.
1. GrandView Research Wound Care 2021.
